# Study of Antibody for Methamphetamine Outpatient Therapy

> **NCT03336866** · PHASE1,PHASE2 · COMPLETED · sponsor: **InterveXion Therapeutics, LLC** · enrollment: 77 (actual)

## Conditions studied

- Methamphetamine-dependence
- Methamphetamine Abuse

## Interventions

- **DRUG:** Placebo
- **DRUG:** IXT-m200

## Key facts

- **NCT ID:** NCT03336866
- **Lead sponsor:** InterveXion Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-03
- **Primary completion:** 2020-11-23
- **Final completion:** 2021-03-09
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336866, "Study of Antibody for Methamphetamine Outpatient Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03336866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*